All manuscripts must be written in the English language (American English) and submitted as Microsoft Word documents with standard 12-point fonts (e.g. Times New Roman, Arial, Symbol), double-spaced with one inch margins. Text should appear in black. Please include all elements except for figures in one MSWord manuscript document. Do not use columns, section numbering, page numbering, headers or footers, tracked changes or comments in your manuscript. Manuscripts must be prepared in accordance with ACS Style Guidelines.
For SLAS Discovery Technical Notes and SLAS Discovery Application Notes, authors MUST combine the Results and Discussion sections into one section. For Original Research and Reviews, authors have the option to separate or combine the Results and Discussion sections.
For Reviews, authors may prepare the main body of text as appropriate for the information being presented and authors should include a final section entitled either Summary or Conclusions (i.e. Cover Sheet, Abstract, Introduction, Main Text/Sections, Summary/Conclusions, References, Tables and Table Legends, Figure Legends).
The Materials and Methods must be adequately described such that they may be duplicated by an independent laboratory by a practitioner skilled in the art. Although it is recognized that confidentiality regarding certain targets or compounds may need to be maintained, lack of disclosure of either will result in low impact ratings and potential rejection. In the case where authors are working on a target of a confidential nature, it is considered reasonable that they publish full details of the results of their assay/screening system using an analogous target protein. Manuscripts that do not disclose both target and compounds tested will not be accepted (with exceptions being virtual screening or statistical modeling). It is expected that proper statistical rigor will be utilized in the design and analysis of all data presented. All experiments must contain proper and relevant controls to ensure proper interpretation of results.
Abbreviations and acronyms should be spelled out when first used. Generic names for drugs and devices are preferred over brand names. Include a manufacturer's location (city, state and country if outside U.S.) in parentheses immediately after citing the manufacturer.
DO NOT embed tables or figures or placement instructions for tables or figures within the text of the main manuscript. Refer to figures and tables in text in accordance with ACS guidelines. Submit figures separately from the main manuscript document (see Figure Guidelines below).
DO NOT use tracked changes, comments, line numbering, page numbers, headers or footers in your main manuscript document. If you wish to emphasize points or passages for editors and reviewers, please do so in your cover letter. The SAGEtrack-generated PDF proof of your submission will include page numbers and line numbering. If necessary, reference those.
Refer to ICMJE guidelines and COPE guidelines for how to define authors and contributors. The acknowledgements section should identify collaborations, sources of research funds and other acknowledgements.
Recommended guidelines for assay development, validation, and data analysis are outlined in the Assay Guidance Manual prepared by Eli Lilly and Company and the National Center for Advancing Translational Sciences.
Authors (especially those who speak English as a second language) may wish to consider working with an author/language services company for help with editing, translation and formatting.
Manuscripts that require approval by an author's employer should be reviewed and cleared before they are submitted to SLAS Discovery or SLAS Technology.
It is the author's responsibility to provide original, high-resolution images (300 dpi) for all figures, photos and illustrations. Images should be at least five inches tall and no more than eight inches wide.
Save images that do not include text or graphs as TIF or JPG files.
Save charts, graphs and line art as EPS files. If absolutely necessary, they can be submitted as Microsoft PowerPoint (PPTX), Word (DOC) or Excel (XLSX) files, but this is not recommended.
Each figure file name should include the lead author's last name and the figure number (e.g. Smith Fig 1, Smith Fig 2, Smith Fig 3, etc.).
For text/labels that appear within images, authors are asked to use Times New Roman font.
There is no charge for images that appear in black and white. Authors who wish to publish color images may do so for a fee to subsidize additional printing expenses. Color charges are $800 for the first color page and $200 for each color page thereafter. Otherwise, figures will print in black and white free of charge and they will appear in color online only. If authors choose the color option for print, an invoice will be sent later in the production process.
Figures should be presented as simply and clearly as possible with the minimum symbology necessary to convey the information contained. Each variable in a figure should be represented in only one way — for example, either by a different symbol or by a different line pattern, but not both. To the extent possible, labels and annotations should be placed directly on the figure rather than in the caption below the figure. Recommended approaches for improving the clarity and style of figures can be found in The Visual Display of Quantitative Information by Edward Tufte. All abbreviations in figures should be spelled out in figure legends.
Prepare each table with a title. User Arabic numerals to number tables. Each table must be understandable independent of the text. Tables should be created in MSWord and be editable. Tables should be included in the MSWord main manuscript document and positioned at the end (after the references), not within the text of the manuscript.
Mathematical equations should be numbered sequentially using Arabic numbers in parentheses, for example, Eq. (1). In the text, equations should be referred to as Eq. (1), Eqs. (2)-(6). All equations should be legible so that every character is easily recognized. All symbols used should be defined in the text. If a special font (other than Symbol) is required for symbols, this should be indicated in a note to the editor.
To complement a manuscript, authors may provide supplemental material for online publication with an article. Supplemental files should be prepared and submitted separately from the main manuscript and figure files.
Supplemental print materials (i.e. text, figures, tables) should be combined and submitted together as one all-inclusive PDF file. If accepted, the file will appear online only EXACTLY AS PROVIDED, so please:
Include a cover sheet/first page that includes the title of the main manuscript that the material supplements, corresponding author name and contact info.
Pay attention to presentation/page layout.
The name of your PDF file will display online as the link to the material, so please consider this when naming and saving it. For example: Supplemental Info for Droplet-Based Microfluidics by Smith, et al.
Supplemental videos/movies may be submitted as .avi, mpeg/mpg, .mov or .wmv files and should not exceed 15 MBs each. The name of your video/movie file will display online as the link to the material, so please consider this when naming and saving the file.
The Peer Review Process
The review process is confidential, and reviewers are obliged not to discuss papers or authors with anyone outside of the SLAS editorial staff. Manuscripts are typically evaluated in response to these general Peer Review Guidelines and initial feedback is usually provided to authors within four weeks after submission. Manuscripts can be accepted as written by reviewers, declined as inappropriate, or as is more often the case, reviewers will suggest revisions. Authors are then offered the opportunity to revise and re-submit their manuscripts, or provide explanations in response to reviewer questions or suggestions. Revisions and responses are re-reviewed by the editor-in-chief and/or peer reviewers before final publishing decisions are made. Invited reviewers are asked to decline their invitations if they have any perceived conflict of interest with the author, the author's affiliation and/or the topic of the paper.
SLAS conducts conventional single-blind reviews in which reviewer names are always concealed from the submitting author. As part of the submission process, authors are asked to provide names, company names and e-mail addresses of experts who could be called upon to review their manuscripts. Recommended reviewers (preferred reviewers) should be experts in the field who can provide objective assessments of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. For example, reviewers recommended by authors should not:
Have prior knowledge of an author’s submission.
Have recently collaborated with any of the authors.
Be from the same institution as any of the authors.
Authors also are asked to share names of individuals that they do NOT want invited to review their work. SLAS editors will consider these recommendations and requests without obligation.
Any text, tables, or figures reproduced from previously published work can only be reprinted with written permission from the copyright holder. Permissions statements must be submitted with the manuscript files, and must include print and online publication. Acquiring permission is the sole responsibility of the author. The publication from which the material is taken must be cited in the references and any required “reprinted with permission” statements must be included as appropriate in text or legends by the author. For more detailed information about permissions, visit the RightsLink website.
When requesting permission, identify JALA and JBS as a “Publisher, STM” (in the RightsLink dropdown menu). SLAS journals are published in partnership with SAGE Publications and SAGE is a member of International Association of Scientific, Technical & Medical Publishers (STM) which usually allows signatory publishers and their authors to use small amounts of other signatory publishers' materials without payment of a fee. For more info, visit www.sagepub.com/authors/journal/permissions.sp
To comply with the guidance for authors, publishers and research funding agencies issued by the Research Information Network (RIN), SLAS Discovery and SLAS Technology require all authors to acknowledge the sources of their funding in the Acknowledgements section of their manuscripts, or to state: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Copyright and Simultaneous Submissions
Manuscripts are considered for publication with the understanding that if a paper is accepted, copyright is transferred to SLAS, and that no paper presenting the same information has been or will be published elsewhere. If part of a contribution has appeared or will appear elsewhere, the author must specify the details in the comments portion of his or her submission.
Simultaneous submissions of manuscripts to multiple journals at the same time is not acceptable — please do not submit manuscripts that may be under consideration by another publication or electronic medium. Published manuscripts may be published elsewhere only with the written permission of SLAS.
Authors whose research was funded by an NIH grant are responsible for submitting the final, accepted version of their manuscripts to PubMedCentral. Please note, however, that SLAS journals content does not become open access until 12 months following the date of final (print) publication of the manuscript. SLAS Discovery and SLAS Technology offer open access options that are compliant with major funding mandates of RCUK, NIH and Wellcome Trust. The open access fee is $3,000. Contact email@example.com for more information.
Conflicts of Interest
All prospective authors must recognize and disclose any conflict of interest, or potential conflict of interest, that may bias their work, or could be perceived to bias their work, and acknowledge all financial support and any other personal connections. SLAS follows the Uniform Requirements for Manuscripts of the International Committee of Medical Journal Editors, especially as they relate to conflicts of interest.
In accordance with the Council of Science Editors, SLAS recognizes that as a general guide, the term "research misconduct" applies to any action that involves purposeful manipulation of the scientific record such that it no longer reflects observed truth, or mistreatment of research subjects. The concepts of negligence and deceit are central to the definition of research misconduct. Research misconduct generally falls into one of four areas: fabrication of data, falsification of data, plagiarism, and unethical treatment of research subjects. [MORE]
If SLAS suspects misconduct by authors, reviewers, editorial staff, or other editors, it will take action. This duty extends to both published and unpublished papers. SLAS will first seek a response from those accused. If SLAS is not satisfied with the response, SLAS will ask the employers of the authors, reviewers, or editors, or some other appropriate body (perhaps a regulatory body) to investigate. In the case of its own editorial staff, SLAS will conduct the investigation itself. SLAS will make all reasonable efforts to ensure that a proper investigation is conducted. If this is not possible, or does not happen for whatever reason, SLAS will make all reasonable attempts to persist in obtaining a resolution to the problem and a correction of the record if it is needed.
Offprints and Reprints
SAGE Publications will provide order forms and pricing information with page proofs of accepted manuscripts.
Letters to the Editor
Comments on published articles are welcome and will be published if deemed appropriate by the editor. Letters should not exceed three double-spaced manuscript pages. Please include a brief title succinctly stating the topic of your letter. Letters to the editor are screened, but also may be peer-reviewed or subjected to rebuttal by the authors of the initial article. Send letters to the editor in MSWord file format to firstname.lastname@example.org.
Send any questions, suggestions, ideas or concerns regarding SLAS journals to:
Director of Publishing
819 Shorewood Boulevard
Manitowoc, WI 54220 USA
Tel: +1.630.256.7527, ext. 106